Entegris, Inc. — Q3 2020 Form 10-Q
Reporting period: Three and nine months ended September 26, 2020; comparisons are to the corresponding 2019 periods unless noted. Entegris supplies microcontamination control products, specialty chemicals and advanced materials handling solutions, primarily to semiconductor and other high-technology manufacturers.
Financial performance
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Net sales | $481.0m | $394.1m | $1,341.7m | $1,164.1m |
| Gross profit / margin | $226.0m / 47.0% | $170.4m / 43.2% | $618.9m / 46.1% | $514.0m / 44.2% |
| Operating income / margin | $106.8m / 22.2% | $52.8m / 13.4% | $282.2m / 21.0% | $155.2m / 13.3% |
| Net income | $79.3m | $40.8m | $208.3m | $197.4m |
| Diluted EPS | $0.58 | $0.30 | $1.53 | $1.45 |
| Adjusted EBITDA (non-GAAP) | $142.4m; 29.6% margin | $107.5m; 27.3% margin | $394.1m; 29.4% margin | $311.8m; 26.8% margin |
- Q3 sales rose 22%; management attributed the increase primarily to stronger semiconductor demand, with $9.7m from acquired businesses and $2.0m from favorable currency translation. Sequential sales increased 7% from Q2 2020.
- Nine-month sales rose 15%, including $37.6m from acquired businesses and $2.1m from favorable currency translation. Higher factory utilization and favorable sales mix supported gross-margin expansion.
- All three segments grew in Q3: Specialty Chemicals and Engineered Materials sales were $150.5m, Microcontamination Control $193.5m, and Advanced Materials Handling $144.4m. Their segment profits were $32.6m, $64.9m and $33.3m, respectively.
- Nine-month GAAP net income increased only modestly despite higher operating income. The prior-year period included $122.0m of net proceeds from the terminated Versum merger, recorded as other income; this makes the comparison less representative of underlying operations.
- Nine-month operating cash flow was $242.7m, versus $253.7m. Working-capital and other balance changes reduced cash generation, including higher receivables and inventory. Investing activities used $190.4m, including $111.1m for acquisitions and $79.6m for capital expenditures. Financing activities provided $44.4m.
- Cash was $448.0m at September 26, 2020, up from $351.9m at year-end 2019. Debt was $1,085.4m, compared with $936.5m; cash less debt therefore represented net debt of approximately $637.4m, versus $584.6m at year-end.
- Working capital was $899.1m. No borrowings were outstanding under the $300m revolving facility; $0.2m of letters of credit were outstanding. The company reported compliance with applicable financial covenants.
Outlook, risks and notable items
- No specific revenue or earnings guidance is provided in the supplied filing text. Management said cash on hand and expected operating cash flows should cover ordinary-course needs for the next 12 months, while emphasizing that COVID-19 impacts remain difficult to predict.
- Management expected 2020 capital expenditures of approximately $120m. Outstanding capital purchase obligations were $47.3m at September 26, 2020.
- COVID-19 created demand and operating uncertainty. Leading-edge semiconductor demand was strong, while some mainstream fabs remained weak, particularly with softness in automotive, aerospace and mobile-phone-related applications. Management cautioned that some customer orders may reflect inventory-building and could shift demand from future periods.
- All facilities were operating at the filing date; Malaysia had returned to full capacity after restrictions reduced productivity. The company reported no significant overall supply-chain interruptions to date, but cited potential supplier, transportation, labor and inventory risks.
- On April 30, 2020, Entegris issued $400m of 4.375% senior notes due 2028 and used proceeds in part to repay revolving-facility borrowings and $251m of term-loan debt. It also acquired Sinmat for approximately $75.6m net of cash acquired and GMTI for approximately $36.3m net of cash acquired.
- The company suspended share repurchases in March 2020 and stated that the program restarted in Q4 2020. It paid $32.4m in dividends during the first nine months and declared a $0.08-per-share dividend payable in November 2020.
- Key risks include semiconductor cyclicality and customer concentration, potential COVID-related recession or order normalization, sole- and limited-source suppliers, foreign-exchange exposure, and trade restrictions/export controls—particularly those affecting China. Approximately 74% of nine-month sales were to customers outside the United States.
- Other notable items: a $3.4m valuation allowance on foreign tax-credit carryforwards was recorded in Q3; nine-month effective tax rate was 16.0%. Management considered ordinary-course legal claims not material to the financial statements. Disclosure controls were assessed as effective.
Investor verification points
- Assess whether Q3 demand strength and margin gains are sustainable, especially given the stated weakness in some end markets and possible customer inventory accumulation.
- Review operating cash conversion and working-capital trends, including receivables, inventory buffers and the $11.9m year-to-date excess-and-obsolete-inventory charge.
- Track debt, interest costs and capital allocation after the 2020 notes issuance, term-loan repayments, acquisition spending and Q4 resumption of share repurchases.
- Separate recurring performance from prior-year Versum proceeds and from acquisition, integration, restructuring and other adjustments; compare GAAP results with the company’s non-GAAP measures.
- Monitor COVID-19 developments, supply continuity, export-control changes, and the company’s progress against its approximately $120m capital-expenditure expectation.